Biotech Values

[DewDiligence]

Astonishing forecast from NVS CC:

Diovan, NVS’ largest-selling drug with annualized worldwide sales of $6B, loses patent protection in the US in 2012 and in all countries by 2014. NVS nonetheless expects Diovan to garner $2B+ in annual worldwide sales as a branded generic in 2015 and beyond! These $2B in sales are expected to come from: i) Japan, where generic substitution for off-patent drugs is traditionally small; and ii) Third World countries in Asia and Latin America where Diovan has no patent protection today but has large sales as a branded generic.